Join Life Science Managing Director, Nishta Rao and First Republic Bank at 12 PM EDT to learn how to keep your startup out of the “Valley of Death” and how a solid banking partner can help and add value to the early stage. Additional speakers include:
– Richard Austin, PhD, MBA, CEO, Reglagene
– Bhawanjit Brar, PhD, Founder & CEO, Jaan Biotherapeutics
– Jessica Gibson, MBA, Co-Founder & CEO, Ariel Medicine
– Danny Talati, PharmD, MBA, Senior Vice President, Corporate Strategy, Cognesy Therapeutics
We hope you’ll join us!
https://us02web.zoom.us/j/83314503728?pwd=UVFDLzB4Qm50UlZmelRRNmRyNWJNUT09
Keep Your Startup Out of the “Valley of Death”
7 Jun- Comments Leave a Comment
- Categories Redefining Every Stage Investments (RESI)
Popular Topics
Listen to the Podcast
Top Posts
- Meet Meki Durakovic: The Hospitality Force Behind Boston’s Culinary Hotspots
- Kobe Biomedical Innovation Cluster (KBIC) Joins RESI JPM 2026 as Gold Sponsor
- Myonerv: RESI London Innovator’s Pitch Challenge Winner Advancing Stroke Rehabilitation
- RESI 2026: Sponsorship That Delivers Visibility, Connection, and Real Engagement
- RESI San Diego 2026 Program Guide Released
- Hot Life Science Investor Mandate 3: Venture Capital Firm Seeking Clinical Stage Therapeutics
- Medical Devices at Digital RESI November
- Hot Life Science Investor Mandate 3: PE Group Targets Biotech Therapeutics, Medtech – January 8, 2013
- Hot Investor Mandate 1: Private Wealth Fund Seeks Healthcare IT & Mobile Health Technologies
- Hot Investor Mandate: USA Investment Firm Invests in Global Early-Stage Life Science Companies, With Strong Interest in Human Augmentation
Recent Posts
- RESI San Diego 2026 Program Guide Released
- Meet RESI Gold Sponsor RSM: Supporting Life Science Companies Through Growth and Transformation
- Building Investor Readiness: Watch the First Two Sessions and Join the Final Webinar
- Hot Investor Mandate: Life Sciences Platform Invests Up to $20M in Early-Stage Therapeutics, Diagnostics, and Medical Technologies
- Hot Investor Mandate: Healthcare-Focused Investment Firm Deploys $10M Initial Checks in Seed to Series B Biopharmaceutical Companies
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]






Leave a comment